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ABSTRACT
Aims: Hemophilia B (HB) is a rare congenital disorder characterized by bleeding-related complications
which are managed by prophylactic or post-bleeding event (“on-demand”) replacement of clotting fac-
tor IX (FIX). The standard of care for severe HB is life-long prophylaxis with standard half-life (SHL) or
extended half-life (EHL) products given every 2–3 or 7–14 days, respectively. FIX treatment costs in the
US have been investigated, but the lifetime costs of HB treatment have not been well characterized,
particularly related to the impact of joint health deterioration and associated health resource utiliza-
tion. We developed a decision-analytic model to explore outcomes, costs and underlying cost drivers
associated with FIX treatment options over the lifetime of an adult with severe or moderately
severe HB.
Materials and methods: With participation from clinicians, health technology assessment specialists
and patient advocates, a Markov model was constructed to estimate bleeding events and costs associ-
ated with health states including “bleed into joint”, “bleed not into joint”, “no bleed” and “death”.
Sub-models of joint health were based on 0, 1, or 2 areas of chronic joint damage. US third-party
payer and societal perspectives were considered with a lifetime horizon; sensitivity analyses tested the
robustness of primary findings.
Results: Total adult lifetime costs per patient with severe and moderately severe HB were $21,086,607
for SHL FIX prophylaxis, $22,987,483 for EHL FIX prophylaxis, and $20,971,826 for on-demand FIX treat-
ment. For FIX prophylaxis, the cost of FIX treatment accounts for >90% of the total HB treat-
ment costs.
Conclusions: This decision analytic model demonstrated significant economic burden associated with
the current HB treatment paradigm.
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Hemophilia B (HB) is a rare congenital blood disorder charac-
terized by deficiency of clotting factor IX (FIX) with spontan-
eous bleeding episodes, most notably into joints, and
delayed hemostasis in external bleeding events1. There are
approximately 6,000 people with HB in the US, with an esti-
mated incidence of one per 20,000 live male births2,3.
Recurrent bleeding into joints can cause long-term joint
deterioration resulting in physical impairment, the need for
joint replacements, chronic pain, and reduced quality of life
(QoL)4. The severity of HB is defined by the level of circulat-
ing FIX and management is based on FIX replacement ther-
apy administered either prophylactically to prevent bleeding
episodes or after a bleeding episode has occurred, known as
“on-demand” treatment5,6. The standard of care for patients
with severe and moderately severe HB is FIX prophylaxis7–10.
FIX supplementation is given intravenously as using standard
half-life (SHL) or extended half-life (EHL) treatments, which
are given every 2–3 or 7–14 days, respectively. The frequent
infusions required by FIX treatment incur a level of treatment
burden that can compromise adherence and clinical effect-
iveness11,12. People with mild or moderate HB who tend to
experience relatively infrequent bleeding episodes are often
managed with on-demand FIX treatment in order to minim-
ize treatment burden.
FIX prophylaxis is effective in reducing the frequency of
bleeding events and improving morbidity and mortality for
patients with HB. However, the cost of treatment is substan-
tial. The mean annual cost of FIX prophylaxis for HB in the
US has been reported to be $610,966, ranging from $397,491
to $788,861 for people with HB using SHL and EHL
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treatments, respectively13. Despite regular use of FIX prophy-
laxis, patients with HB still experience breakthrough bleeding
events, which require medical management (i.e. hospitaliza-
tions, office visits) in addition to FIX treatment13,14. The
CHESS US13 burden of illness study found patients with
severe hemophilia reported an annual mean of 0.18 hospital-
izations with an average of 0.23 days spent in the intensive
care unit each year due to bleed-related complications.
The reported costs of HB have been historically limited, or
reported in per-patient terms over relatively short time peri-
ods15. The effects of joint health deterioration over longer
time periods more closely approximating the disease course
duration for this lifelong congenital condition have not been
well characterized. Specifically, the ultimate costs related to
medical management of HB, including office visits, hospital-
izations and joint replacement, as well as the ongoing FIX
treatment costs, have not been clarified from a population
health management perspective.
CHESS US reported bleeding rates, healthcare resource
use and costs available in a sample of medical charts, but
was designed as a cross-sectional study using a focused sam-
ple of patients13. The Hemophilia Utilization Group Studies
Part Vb (HUGS Vb) study reported overall bleeding events
and costs but was limited to 1–2 years of medical and dis-
pensing records from Hemophilia Treatment Centers
(HTCs)14. Recently published economic models for emicizu-
mab, a bispecific antibody administered subcutaneously and
indicated for the prevention of bleeding events in people
with hemophilia A, and a hypothetical gene therapy16,17
have tried to estimate the effect of joint deterioration on life-
long costs and outcomes, but were focused on patients with
hemophilia A and did not provide similar insights for HB. As
such, we developed a decision-analytic model to explore out-
comes, costs and cost drivers of HB management from both
US third-party payer and societal perspectives on a lifetime
horizon of adults with severe and moderately severe HB (IU/
dL 2). In order to account for the breadth and depth of
critical considerations in this research area, we invited an
expert panel of clinicians, patient advocates, and health tech-
nology assessment (HTA) specialists to participate in the
design and construction of the model.
Methods
Model overview
A Markov cohort model was constructed to estimate the
adult lifelong cost of HB management. The initial model con-
cept was informed by a targeted review of published eco-
nomic modeling studies in hemophilia and presented to an
expert panel consisting of hematologists, HTA specialists and
patient advocacy representatives (more information provided
in Appendix 1). The panel’s input on the model set-up, struc-
ture and key assumptions formed the basis of its final
design. Panel input was incorporated in all aspects of the
final model, including the structure, statistical approach,
patient population, input parameters, perspective, timeframe,
and specific sources and considerations related to each of
the input parameters.
A hypothetical cohort of male adults (18 years old) with
severe and moderately severe HB and no history of inhibitors
entered the model. Three treatment options were included:
SHL FIX prophylaxis, EHL FIX prophylaxis, and on-demand
FIX treatment. SHL FIX prophylaxis was based on the use of
nonacog alfa7,8,18; other SHL products have limited real-world
usage in the US and were excluded19. EHL FIX prophylaxis
included albutrepenonacog alfa, eftrenonacog alfa, and non-
acog beta pegol. On-demand FIX treatment included both
SHL and EHL products. For each treatment arm, the number
of bleeding episodes and joint bleeds occurring within the
time horizon of the model were recorded. Costs and benefits
were discounted at an annual rate of 3%, which is standard
in US economic models and in line with the Institute for
Clinical and Economic Review (ICER) Value Assessment
Framework20. The model considered both US third-party
payer and societal perspectives, where the payer perspective
focused on direct medical costs and the societal perspective
also included non-medical costs (resources supporting
healthcare sector services) and indirect costs (e.g. productiv-
ity losses). The decision analytic model was developed in
Microsoft Excel (Redmond, WA).
Model framework
The Markov cohort model (Figure 1) was constructed with
mutually exclusive health states based on naturally occurring
events during the lifetime of people with HB. The health
states included in the model were: “No bleed”, “Bleed (not
joint)”, “Bleed (joint)” and “Death”. All patients began in the
“No Bleed” health state and could transition over time to a
“bleed” event or “dead” health state. Depending on the type
of bleeding episode, patients transitioned to either “Bleed
(joint)” or “Bleed (not joint)” based on the weekly transition
probability, derived from the annual bleed rate (ABR)
reported in clinical trials for each arm. The probability of
death at the given point of time in the model was calculated
based on age-specific male general population mortality in
the US21. A one-week cycle length with half-cycle correction
was employed. As advised by the expert panel, a lifetime
horizon was applied in the base case analysis. Shorter time
horizons were tested in scenario analyses for 3, 5
and 10 years.
In order to quantify the impact of bleeding rate on joint
damage over time, three sub-models were defined using the
current number of problem joints (PJs) acquired. PJs are a
measure of chronic joint damage and defined by symptoms
such as limited range of motion, pain, and hemophilic
arthropathy22. According to the expert panel, this definition
was deemed a better representation of long-term joint
health than the target joint (TJ) definition22, which is defined
as three bleeding events into a given joint during a 6-month
period. It was recognized that the burden associated with
repeated bleeding would be captured by the main model
structure, as this was based on bleeding events. In each
model cycle, to reflect progressing joint deterioration, a pro-
portion of patients irreversibly moved from 0 PJ through 1
PJ to 2þ PJs sub-models (Figure 1). The distribution of the
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cohort across joint damage sub-models at model entry was
assumed to be 80% for 0 PJ, 10% for 1 PJ, and 10% for 2þ
PJs. The probability of transition between PJ sub-models was
based on Fischer et al.23, where 12.6 joint bleeds on average
generated an increase in Pettersson score and reflected pro-
gression in the deterioration of joint health. Based on this
assumption, the weekly probability of transition to the next
PJ sub-model was calculated considering annual joint bleed
rate (AJBR) of each treatment arm.
Model inputs
The base case model inputs and ranges of model inputs
used for sensitivity analyses are summarized in Table 1. All
costs were translated to 2019 USD($) and adjusted to the
length of the weekly treatment cycle as appropriate. Annual
bleed rates and AJBRs were based on the pivotal trial results
of the FIX products and used to calculate non-joint bleed
rates. It was assumed that patients in the 1 PJ and 2þ PJs
sub-models could undergo an orthopedic surgery once or
twice per lifetime (between the ages of 45 and 89 years),
respectively16,17.
Prophylaxis and on-demand dosing information was
based on US prescribing information (US PI) for FIX products.
The unit price for FIX products was based on the wholesale
acquisition cost (WAC), as reported in Redbook. The dose per
infusion of FIX therapy was calculated using national average
weight in the US, using published weight tables28 for the
age-matched US male population. Market research data on
real-world usage were used to derive the treatment mix of
people with HB using alternative EHL products in the EHL
prophylaxis arm and of people with HB using SHL and EHL
products in the on-demand arm19. Data from five clinical tri-
als8,9,24,29,30 across SHL and EHL products were used to calcu-
late an average of 1.2 FIX infusions needed to treat a
bleeding event.
Non-drug costs of HB management included hospitaliza-
tions due to bleeding, orthopedic surgery, or intracranial
hemorrhage, and outpatient visits. The frequency and aver-
age length of stay of bleed-related hospitalizations and the
frequency of office visits were derived from the CHESS US
Figure 1. Model structure.
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study13. The unit cost for hospitalization and office visits
were sourced from literature and the CMS Physician Fee
Schedule. Non-medical costs included expenses incurred due
to travelling to the HTC and were sourced from the CHESS
US study13. The components of indirect cost included prod-
uctivity losses and social benefits. The human capital
approach31 was used to estimate productivity losses. Data
sourced from the CHESS US(þ) study32 (a patient-centric fol-
low-up study to CHESS US that gathered data on indirect
costs of hemophilia) were used to estimate both productivity
losses and social benefits cost.
Sensitivity analysis
Model inputs were tested in one-way sensitivity analysis
(OWSA) primarily based on the 95% confidence interval for
each parameter. For variables with no available estimates of





Annual bleed rate (ABR)
SHL FIX prophylaxis 4.052 3.8–4.3 Mean ABR weighted by the number
of patients in nonacog alfa trials
Kavakli et al.7, Roth et al.18,
Lambert et al.8
EHL FIX prophylaxis 2.27 2.12–2.43 Mean ABR weighted by the number




et al.29; nonacog beta pegol:
Collins et al.24
On-demand FIX 33.87 33.64–34.09 Mean ABR weighted by the number
of patients in trials
Kavakli et al.7, Valentino et al.25
Annual joint bleed rate (AJBR)
SHL FIX prophylaxis 2.1 0.85–3.35 – Kavakli et al.7
EHL FIX prophylaxis 0.89 0.71–1.06 Mean AJBR weighted by the
number of patients in trials
Albutrepenonacog alfa:
Santagostino et al.6, 9;
eftrenonacog alfa: Powell et al.29
On-demand FIX 26.17 25.94–26.39 Mean AJBR weighted by the
number of patients in trials
Kavakli et al.7, Valentino et al.25
Orthopedic surgery
0 problem joints 0 – – Assumption16,17
1 problem joint 1/lifetime 0.65–1.43b – Assumption16,17
2þ problem joints 2/lifetime 1.29–2.86b – Assumption16,17
CNS bleed 0.00183 0.00118–0.00261b – Witmer et al.10
Dosing
Prophylaxis dose (IU/kg)
SHL 51.70 33.46–73.85b – Lambert et al.8




SHL 3.5 2.27–5b – Lambert et al.8
EHL 7 4.53–10b – US PIs for nonacog alfa,
albutrepenonacog alfa and
GlycoPEGylated FIX
On-demand dose (IU per kg)
SHL 100 60–100c – US PI for nonacog alfa




SHL (IU) 1.37 0.89–1.96b Nonacog alfa Redbook 2019
EHL (IU) 4.40 2.85–6.28b Albutrepenonacog alfa Redbook 2019
EHL (IU) 3.12 2.02–4.46b Eftrenonacog alfa Redbook 2019
EHL (IU) 4.00 2.59–5.71b Nonacog beta pegol Redbook 2019
Hospitalization due to bleed 11,376.03 – Calculated by multiplying the
frequency of hospitalization due
to bleed by the length of stay
and the cost per bed day
Bed day cost: HCUP26
Frequency of hospitalization and
length of stay: CHESS US13
Orthopedic surgery 140,071 90,647–200,078b – Machin et al.16
CNS bleed 106,083 6,8651–15,1529b – Patel et al.27
Outpatient carea
0 PJ 526 – Calculated by multiplying
frequencies of individual outpatient
services by their cost
Cost: CMS Physician Fee Schedule
Frequencies: CHESS US131 PJ 826 –
2þ PJ 1,237 –
Abbreviations. ABR, Annual bleed rate; AJBR, Annual joint bleed rate; CMS, Centers for Medicare & Medicaid Services; CNS, Central nervous system; EHL,
Extended half-life; HCUP, Healthcare Cost and Utilization Project; SHL, Standard half-life; US PI: United States prescribing information.
aAnnual cost.
bRange calculated as a 95% confidence interval assuming 20% variation in those parameters.
cBased on the clinically plausible ranges.
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certainty, 20% variation was assumed. Further testing was
conducted for selected variables (discounting rates, on-
demand FIX doses, duration of GTx treatment effect, GTx dis-
count for partial responders and orthopedic surgery age)
using specified ranges representing plausible ranges to
inform the sensitivity of the outcomes.
Results
Base case results
Model results showed substantial cost of severe and moder-
ately severe HB management associated with all three treat-
ment options (Table 2). From the societal perspective, the adult
lifetime total cost per patient was $21,086,607 for SHL FIX
prophylaxis, $22,987,483 for EHL FIX prophylaxis, and
$20,971,826 for on-demand FIX treatment. From the payer per-
spective, the adult lifetime direct medical cost per patient was
$21,032,332 for SHL FIX prophylaxis, $22,933,207 for EHL FIX
prophylaxis, and $20,934,426 for on-demand FIX treatment.
Most of the direct medical cost for HB management was driven
by FIX treatment, estimated at $19,754,862 and $22,202,092 for
prophylaxis with SHL and EHL, respectively (both accounted for
more than 90% of direct medical costs). On-demand FIX
treatment accounted for approximately 60% of direct medical
costs, at $12,179,003. Non-medical direct and indirect costs con-
stituted a relatively small proportion of the total cost of HB
management (from 0.18% to 0.26% in lifetime horizon). When
the model was run with shorter time horizons, the total cost
per patient ranged from $2.2 to $2.4 million over 3 years, $3.6
to $3.9 million over 5 years, and $6.7 to $7.3 million over
10 years across all three treatment arms (Figure 2).
Patients receiving EHL FIX prophylaxis had the fewest
total bleeding events (132) and joint bleeds (52) over the
adult lifetime horizon. Patients receiving SHL FIX prophylaxis
had 234 total bleeding events and 121 joint bleeds, and
patients receiving on-demand FIX treatment had 1,632 total
bleeding events and 1,211 joint bleeds (Table 2). Similar
trends were observed for total and joint bleed results within
the shorter time horizon scenarios (Figure 3).
Sensitivity analysis results
One-way sensitivity analysis results were generally consistent
with the base case results. Total adult lifetime cost of HB
management was most sensitive to variations in the unit
cost of FIX treatment, discount rates, and the number of
Table 2. Base case analysis results in US adults with hemophilia B (lifetime horizon).
SHL FIX prophylaxis EHL FIX prophylaxis On-demand FIX
Cost
Direct medical cost $21,032,332 $22,933,207 $20,934,426
FIX treatment $19,754,862 $22,202,092 $12,179,003
Other medical costa $1,277,470 $731,115 $8,755,423
Non-medical direct and indirect costs $54,276 $54,276 $37,400
Total cost $21,086,607 $22,987,483 $20,971,826
Bleeds
Total 234 132 1,632
Joint bleeds 121 52 1,211
Abbreviations. EHL, Extended half-life; FIX, Factor IX; SHL, Standard half-life.
aIncludes hospitalization cost (due to bleeding, orthopedic surgery, intracranial hemorrhage) or outpatient care costs.
Figure 2. Total costs associated with different time horizons. Abbreviations. EHL, Extended half-life; m, Million; OD, On-demand; SHL, Standard half-life.
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injections needed to treat a bleeding event, regardless of the
treatment arm (Figure 4 for SHL FIX prophylaxis,
Supplemental Figures 1 and 2 for EHL FIX prophylaxis and
on-demand FIX treatment).
Discussion
This decision analytic model showed substantial costs of
managing severe and moderately severe HB across the adult
lifetime in the US, exceeding $20 million in all scenarios.
Occurrence of bleeding events including joint bleeds per-
sisted despite FIX prophylaxis, which accounted for >90% of
direct costs, but were markedly greater for patients receiving
on-demand treatment only (10- to 20-times more bleeding
events in some scenarios). As FIX treatment costs accounted
for so much of the total costs, the model was most sensitive
to the unit costs of FIX treatment, discount rates, and the
number of FIX administrations required to treat a bleeding
Figure 3. Total bleeds for different time horizons. Abbreviations. EHL, Extended half-life; OD, On-demand; SHL, Standard half-life.
Figure 4. OWSA results for a total cost of SHL FIX prophylaxis in adult life-time horizon. Abbreviations: ABR, Annual bleed rate; IU, International unit; PJ, Problem
joint; SHL, Standard half-life.
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event. This model illustrated a tangible unmet need related
to bleeding events and the need for lower costs to prevent
and treat bleeding events, from both societal and third-party
payer perspectives.
Our model findings are consistent with published real-
world utilization studies that the cost of FIX prophylaxis
accounts for >90% of direct medical costs of HB manage-
ment14,33,34. Moreover, substantial lifetime cost of disease
management can be also seen in other rare diseases such as
Gaucher disease (e6 million)35 and paroxysmal nocturnal
hemoglobinuria ($9 million)36.
Our study offers a lifetime perspective on treatment cost
drivers, where FIX prophylaxis constituted approximately
95% of total medical costs, regardless of EHL or SHL prod-
ucts used. On-demand FIX treatment costs accounted for
roughly 60% of total HB costs, but resulted in much higher
rates of bleeding events and a similar overall lifetime cost
($21 million) as either SHL or EHL prophylaxis ($21 and $23
million, respectively). Across the adult lifetime horizon, SHL
and EHL FIX prophylaxis were associated with 85–90% reduc-
tions in total bleeds (132–234 vs. 1,632 total bleeds) and
90–95% reduction in joint bleeds (52–121 vs. 1,211 joint
bleeds) compared to on-demand FIX treatment. Taken
together, the model suggested that an on-demand treatment
strategy did not confer any meaningful direct cost savings
compared to prophylaxis, with non-drug medical costs
increasing over the long term likely attributable to poorer
clinical outcomes. These findings were consistent with previ-
ous cost-effectiveness models37–41 in hemophilia A compar-
ing factor VIII prophylaxis with on-demand treatment. The
broader view offered by these results also highlights that the
residual burden of bleeding events with FIX prophylaxis is
significant (134–234 total bleeds, 52–121 joint bleeds), par-
ticularly considering progressive joint damage. The limited
motion and joint pain associated with hemophilic arthrop-
athy are known to further worsen patients’ QoL and well-
being, underscoring the persistent unmet medical need in
this population42,43. It is well documented that there is the
clinical benefit of prophylaxis in bleed prevention, joint
health, and improving QoL5–7,44. Recent cost-effectiveness
analyses (CEAs) also showed prophylaxis is cost-effective
compared to on-demand treatment39,40,45–47.
Additionally, Supplemental Table 1 provides an overview
of identified cost-effectiveness studies reporting costs of life-
long hemophilia A management in the US17,41,48–50. The
majority utilized Markov models and more recent studies
included health states capturing joint deterioration, similar to
the approach used for our study. Discrepancies in lifetime
costs reported by those studies can be partially explained by
differences in follow-up periods (due to patients’ ages when
entering the model) and cost categories included in the anal-
yses. Although the majority of costs were associated with FIX
treatment costs, the considerable scope and impact of indir-
ect costs and non-medical costs should not be overlooked
when assessing the overall burden of HB on patients, their
caregivers and society. Based on results from 112 patients
across 10 HTCs, the HUGS Vb14 study captured the impact of
HB on absenteeism, presenteeism, productivity levels and
overall employment status, as well as unpaid hemophilia-
related caregiver time. The study reported a significant
impact of HB on employment status and work productivity
in the US, indicating that indirect costs constitute 9% of the
total HB costs. In contrast, our model focused primarily on
direct costs and only managed to capture some non-medical
and indirect costs, which accounted for less than 1% of total
cost. This disparity might be partially explained by the differ-
ent indirect cost components considered by both studies.
Cost-effectiveness analyses based on decision analytic
models are commonly used by health policy makers to
determine the value of novel treatments. Waters and Karpf51
postulated that CEA could be used to inform the need for
cost control, provision of efficient and effective care, as well
as evaluation of alternative payment models. Increasingly,
more payers and manufacturers use value-based pricing
approaches to determine prices for pharmaceutical products,
which allows them to determine a price that reflects health
gains generated by the treatment of interest. Decision ana-
lytic models play a central role in estimating these parame-
ters. Most payers during reimbursement decision-making
focus on the evaluation or direct costs, but in some regions
or countries indirect costs are also considered. As shown by
this research, in hemophilia the total cost is primarily driven
by direct medical costs, but inclusion of the societal perspec-
tive may be of paramount importance to the cost-effective-
ness of therapies in other conditions that are also associated
with substantial impairment of patients’ productivity.
Modern treatment advances to date have offered mean-
ingful improvements over historical therapeutic options in
terms of clinical outcomes, life expectancy, and QoL; how-
ever, this model has quantified that severe and moderately
severe HB still poses a significant burden to payers and soci-
ety, driven primarily by the high costs of FIX treatment. It
should be noted that several novel treatments are in devel-
opment for HB, including gene therapy, and may be consid-
ered in future iterations of this work. Based on available
phase 1/2 clinical trial52,53 findings, HB gene therapy may
provide >90% reduction in FIX usage together with further
reductions in bleed rates compared to FIX prophylaxis
among patients with severe and moderately severe HB, pre-
senting an opportunity for substantial cost offsets in
HB management.
Interpretation of this decision analytic model should con-
sider certain strengths, limitations, and contextual factors.
The model framework and assumptions combined published
estimates with robust input from a panel of clinicians, HTA
specialists, and patient advocates, and was aligned with the
approach of a recent ICER model for the evaluation of emici-
zumab for patients with hemophilia A and inhibitors17. The
panel input ensured that detailed model assumptions
allowed for close approximation of a natural disease history
including relevant clinical events and associated costs.
Representatives from clinical, patient, and health policy
stakeholders ensured that the perspective and model param-
eters accounted for their considerations in HB management.
Similarly, our model and the ICER model both attempted
to simulate a natural disease progression, with emphasis on
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joint deterioration, and used similar approaches for transition
probabilities across sub-models of joint health. We utilized a
joint health definition of “problem joints” that considered
published health outcomes research on the impact of TJs on
patients’ lives and QoL44, whereas the ICER model used a
more clinical definition based on the presence of arthrop-
athy. The ICER model also used a structure for bleed-related
health states that differentiated between treated and
untreated bleeding events. Published data sources used for
our model inputs were consistent with other published eco-
nomic evaluations in hemophilia16,17,38. The lack of appropri-
ate information about the number of PJs accrued by people
with HB at different ages was a limitation to the model. The
solution to this problem was to assume a baseline distribu-
tion of patients with 0, 1 and 2þ PJs. This distribution was
then modified within the scenario analysis and consistent
estimates were still generated, indicating the robustness of
the model findings. The model did not capture the impact of
HB on caregivers, which would have increased the indirect
cost estimates.
Patients included in this model represented those at
greatest risk of spontaneous bleeds, a pool of patients also
frequently represented in clinical trials of FIX treatment can-
didates, and the annual bleeding rate estimates were based
on those from clinical trials. Considering the differences
between trial participants and those encountered in regular
clinical practice, rates of treatment adherence may have
been overestimated, and overall bleeding events and joint
bleeds may have been underestimated compared to “real-
world” rates in a more heterogeneous population. The model
may have underestimated the magnitude of clinical, human-
istic, and economic burden both for patients entering the
model and as they progressed over time with current stand-
ards of care.
To our knowledge, this is the first economic model to
assess lifetime health outcomes and costs for adults with HB
over the natural history of disease, with particular focus on
the impact of long-term joint deterioration. This model dem-
onstrated the significant economic burden of current treat-
ment options that exceeded $20 million in any clinical and
treatment scenario. Total direct costs were overwhelmingly
driven by FIX treatment costs, yet bleeding events and long-
term consequences of accumulated bleeds persisted, includ-
ing joint deterioration and associated medical management.
Indirect and non-medical costs appeared provincial in the
shadow of FIX treatment costs, but should not be underre-
presented in the holistic calculus of long-term burden of HB
and the potential to offer patients long-term relief from the
meaningful negative impact on employment and life.
Despite advances in the available therapeutic approaches to
prevent and treat breakthrough bleeding, notable unmet
needs remain to further improve clinical, humanistic, and
economic outcomes for patients with HB and society.
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